Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. Their approach directly stops tumor growth and selectively stops immunosuppression in tumors without targeting the current immune checkpoint pathway, improving efficacy, reducing toxicity and increasing treatment affordability of cancer drugs compared to single-action drugs.